Cancer Stem Cells in Pancreatic Ductal Adenocarcinoma.

cancer stem cells epigenetics epithelial–mesenchymal transition pancreatic ductal adenocarcinoma signalling pathways

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
10 Apr 2023
Historique:
received: 10 03 2023
revised: 05 04 2023
accepted: 06 04 2023
medline: 1 5 2023
pubmed: 28 4 2023
entrez: 28 4 2023
Statut: epublish

Résumé

The first discovery of cancer stem cells (CSCs) in leukaemia triggered active research on stemness in neoplastic tissues. CSCs represent a subpopulation of malignant cells, defined by unique properties: a dedifferentiated state, self-renewal, pluripotency, an inherent resistance to chemo- and radiotherapy, the presence of certain epigenetic alterations, as well as a higher tumorigenicity in comparison with the general population of cancer cells. A combination of these features highlights CSCs as a high-priority target during cancer treatment. The presence of CSCs has been confirmed in multiple malignancies, including pancreatic ductal adenocarcinoma, an entity that is well known for its dismal prognosis. As the aggressive course of pancreatic carcinoma is partly attributable to treatment resistance, CSCs could contribute to adverse outcomes. The aim of this review is to summarize the current information regarding the markers and molecular features of CSCs in pancreatic ductal adenocarcinoma and the therapeutic options to remove them.

Identifiants

pubmed: 37108193
pii: ijms24087030
doi: 10.3390/ijms24087030
pmc: PMC10138709
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Curr Cancer Drug Targets. 2013 Nov;13(9):963-972
pubmed: 24168186
Cancer Lett. 2011 Dec 27;313(2):137-44
pubmed: 22030254
Cells. 2016 Mar 29;5(2):
pubmed: 27043634
J Exp Med. 2007 Nov 26;204(12):2935-48
pubmed: 17984306
Cell Death Dis. 2018 Jan 5;9(1):2
pubmed: 29305578
Genes (Basel). 2011 Feb 25;2(1):229-59
pubmed: 24710147
Front Oncol. 2022 Oct 25;12:980659
pubmed: 36387257
Anticancer Res. 2011 Apr;31(4):1105-13
pubmed: 21508353
Cell. 2008 May 16;133(4):704-15
pubmed: 18485877
Gastroenterology. 2003 Sep;125(3):891-905
pubmed: 12949733
Anticancer Res. 2019 Jul;39(7):3317-3321
pubmed: 31262852
Cancer Res. 2015 May 1;75(9):1883-96
pubmed: 25769727
Int J Mol Sci. 2022 Jan 24;23(3):
pubmed: 35163198
PLoS One. 2012;7(4):e35720
pubmed: 22558209
PLoS One. 2013 Sep 17;8(9):e73968
pubmed: 24069258
Cytometry. 1990;11(2):231-8
pubmed: 1690625
Cancer Lett. 2013 Sep 10;338(1):94-100
pubmed: 22445908
Cells. 2020 Oct 09;9(10):
pubmed: 33050292
J Vis Exp. 2019 Sep 13;(151):
pubmed: 31566597
Br J Cancer. 2008 Apr 22;98(8):1389-97
pubmed: 18349830
Cancer Cell. 2013 Jun 10;23(6):811-25
pubmed: 23764003
Oncotarget. 2017 Aug 11;9(1):1346-1355
pubmed: 29416699
Biomedicines. 2022 May 11;10(5):
pubmed: 35625853
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Int J Mol Sci. 2021 Apr 30;22(9):
pubmed: 33946266
Philos Trans R Soc Lond B Biol Sci. 2014 Dec 5;369(1657):
pubmed: 25349448
Semin Cancer Biol. 2012 Oct;22(5-6):396-403
pubmed: 22554795
Cell. 2009 Aug 21;138(4):645-659
pubmed: 19682730
Stem Cells Int. 2016;2016:8352684
pubmed: 27006664
Proc Natl Acad Sci U S A. 2011 Aug 9;108(32):13253-7
pubmed: 21788521
Cancers (Basel). 2021 Nov 03;13(21):
pubmed: 34771675
Cold Spring Harb Perspect Med. 2014 May 01;4(5):
pubmed: 24789872
J Cell Biol. 2007 Apr 9;177(1):151-62
pubmed: 17403932
Am J Cancer Res. 2015 Feb 15;5(3):894-906
pubmed: 26045976
Mol Cells. 2018 Feb 28;41(2):83-92
pubmed: 29429151
Blood. 1997 May 1;89(9):3385-95
pubmed: 9129046
Cancer Res. 2010 Jun 1;70(11):4280-6
pubmed: 20484026
Exp Cell Res. 2018 Oct 1;371(1):63-71
pubmed: 30056064
Cancers (Basel). 2016 Feb 15;8(2):
pubmed: 26891329
Am J Cancer Res. 2021 Oct 15;11(10):5141-5154
pubmed: 34765317
J Biol Chem. 2018 Apr 6;293(14):5247-5258
pubmed: 29440274
Int J Oncol. 2017 Nov;51(5):1357-1369
pubmed: 29048660
Semin Oncol. 2021 Feb;48(1):10-18
pubmed: 33676749
Curr Oncol. 2022 Sep 23;29(10):6864-6892
pubmed: 36290818
Int J Mol Sci. 2021 Nov 29;22(23):
pubmed: 34884696
Development. 2015 Feb 15;142(4):607-19
pubmed: 25670788
J Biol Chem. 2011 Sep 16;286(37):32843-53
pubmed: 21795717
J Hematol Oncol. 2018 May 10;11(1):64
pubmed: 29747682
Cancer. 2014 Sep 1;120(17):2766-77
pubmed: 24839953
Pancreas. 2016 Mar;45(3):443-57
pubmed: 26646272
Cancer Res. 2016 Aug 1;76(15):4546-58
pubmed: 27261509
Int J Oncol. 2012 Oct;41(4):1314-24
pubmed: 22824809
Neoplasia. 2016 Nov;18(11):689-698
pubmed: 27792935
Front Immunol. 2022 Oct 13;13:1016647
pubmed: 36311715
J Biol Chem. 2002 Oct 18;277(42):39209-16
pubmed: 12161443
World J Stem Cells. 2020 Jun 26;12(6):448-461
pubmed: 32742562
Cancer Lett. 2017 Nov 28;409:9-19
pubmed: 28864067
Cancer Metastasis Rev. 2021 Sep;40(3):691-720
pubmed: 34453639
Cell. 2015 Nov 19;163(5):1237-1251
pubmed: 26590425
Oncotarget. 2015 Apr 30;6(12):9999-10015
pubmed: 25846752
Front Oncol. 2019 Sep 10;9:874
pubmed: 31552188
Clin Cancer Res. 2012 Jan 15;18(2):465-74
pubmed: 22096026
Cancer Cell Int. 2019 May 22;19:145
pubmed: 31139022
Cell Res. 2009 Feb;19(2):156-72
pubmed: 19153598
Cell Biosci. 2017 Aug 7;7:39
pubmed: 28794854
Inflamm Regen. 2022 Nov 30;42(1):54
pubmed: 36451253
BMC Cancer. 2014 Sep 21;14:687
pubmed: 25240521
Nat Biomed Eng. 2022 Oct;6(10):1148-1166
pubmed: 36261625
Tumour Biol. 2017 Jul;39(7):1010428317712617
pubmed: 28671020
Semin Cancer Biol. 2018 Dec;53:223-231
pubmed: 30130664
Adv Biol Regul. 2019 May;72:63-77
pubmed: 30853342
Int J Mol Sci. 2023 Feb 21;24(5):
pubmed: 36901685
Cancer Genomics Proteomics. 2020 Nov-Dec;17(6):695-705
pubmed: 33099471
Mol Cancer Ther. 2014 Jul;13(7):1758-71
pubmed: 24785258
Cancers (Basel). 2020 Dec 17;12(12):
pubmed: 33348546
Cancer Res. 2005 Dec 1;65(23):10783-93
pubmed: 16322224
Int J Biochem Cell Biol. 2019 Jan;106:1-7
pubmed: 30399449
Mol Cancer. 2017 Feb 28;16(1):52
pubmed: 28245823
Cell Metab. 2015 Oct 6;22(4):590-605
pubmed: 26365176
J Cell Physiol. 2023 Feb;238(2):306-328
pubmed: 36502519
Cancer Lett. 2016 Jan 28;370(2):260-7
pubmed: 26546043
BMC Cancer. 2021 Apr 9;21(1):385
pubmed: 33836674
Adv Cancer Res. 2014;124:31-82
pubmed: 25287686
Genes (Basel). 2018 Feb 19;9(2):
pubmed: 29463061
Clin Exp Pharmacol Physiol. 2021 Sep;48(9):1185-1202
pubmed: 34046925
Cell Stem Cell. 2007 Sep 13;1(3):313-23
pubmed: 18371365
Semin Cancer Biol. 2022 Dec;87:48-83
pubmed: 36347438
Surgery. 2016 Jun;159(6):1520-1527
pubmed: 26847803
Cancer Lett. 2017 Dec 1;410:68-81
pubmed: 28947139
Genes Dev. 2012 Sep 1;26(17):1926-44
pubmed: 22899010
PLoS One. 2011;6(8):e24099
pubmed: 21909380
PLoS One. 2011;6(11):e27306
pubmed: 22087285
Pancreatology. 2007;7(5-6):423-35
pubmed: 17898532
Surg Oncol. 2022 Dec;45:101858
pubmed: 36272250
Cells. 2021 Mar 11;10(3):
pubmed: 33799798
Anticancer Res. 2017 Jun;37(6):2761-2775
pubmed: 28551612
Cancer Commun (Lond). 2023 Jan;43(1):3-41
pubmed: 36424360
Cancers (Basel). 2019 Jun 21;11(6):
pubmed: 31234336
Cancer. 2022 Dec 15;128(24):4251-4284
pubmed: 36301149
Pathol Oncol Res. 2018 Oct;24(4):797-805
pubmed: 29948612
Cell. 2012 Jan 20;148(1-2):349-61
pubmed: 22265420
Cancer Res. 2011 Jul 15;71(14):5020-9
pubmed: 21586612
Mol Ther. 2023 Feb 1;31(2):503-516
pubmed: 36384875
Front Cell Dev Biol. 2021 Apr 28;9:671022
pubmed: 33996827
BMB Rep. 2018 Mar;51(3):106-118
pubmed: 29397869
Cancers (Basel). 2021 Jun 23;13(13):
pubmed: 34201898
J Cancer. 2016 Jan 20;7(4):408-17
pubmed: 26918054
Breast Cancer Res. 2016 May 24;18(1):55
pubmed: 27220421
Oncotarget. 2016 Mar 8;7(10):11018-32
pubmed: 26783961
Cell Death Dis. 2014 Jul 17;5:e1336
pubmed: 25032859
Clin Cancer Res. 2015 Oct 1;21(19):4482-93
pubmed: 26041746
Oncotarget. 2016 Sep 20;7(38):61136-61151
pubmed: 27531902
Int J Mol Med. 2018 Oct;42(4):1771-1785
pubmed: 30015855
Biomark Res. 2013 Jan 16;1(1):5
pubmed: 24252238
Cancer Res. 2007 Feb 1;67(3):1030-7
pubmed: 17283135
J Transl Med. 2021 Sep 22;19(1):400
pubmed: 34551785
Front Cell Dev Biol. 2021 May 17;9:663906
pubmed: 34079799
Trends Mol Med. 2013 May;19(5):320-7
pubmed: 23545339
Cancer Prev Res (Phila). 2012 Mar;5(3):355-64
pubmed: 22086681
J Biol Chem. 2007 May 11;282(19):14048-55
pubmed: 17353198
Cell Stem Cell. 2011 Nov 4;9(5):433-46
pubmed: 22056140
Signal Transduct Target Ther. 2020 Feb 7;5(1):8
pubmed: 32296030

Auteurs

Roman Bubin (R)

Faculty of Medicine, Riga Stradins University, 16 Dzirciema Street, LV-1007 Riga, Latvia.

Romans Uljanovs (R)

Department of Pathology, Riga Stradins University, 16 Dzirciema Street, LV-1007 Riga, Latvia.

Ilze Strumfa (I)

Department of Pathology, Riga Stradins University, 16 Dzirciema Street, LV-1007 Riga, Latvia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH